Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merz Pharmaceuticals GmbH
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Subjective worsening of memory, concentration or attention problems for longer than 6 months

• Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject

• Experience of the memory, concentration or attention problems at least four times per week

Exclusion Criteria:

• Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia)

• Significant systemic illness, such as cancer, heart or kidney failure, uncontrolled diabetes

• History of stroke or seizure, or myocardial infarction within the last year (e.g. by inclusion questionnaire, physician interview)